Mellor R, Kearnes M, Lancaster K, McLauchlan L, Ritter A. Established tables and emergent huddles: exploring the processes of participation associated with the policy changes to opioid pharmacotherapy treatment in Australia in the context of COVID-19. Contemp Drug Probl. 2022 Sep 8;49(4):385-404. doi: 10.1177/00914509221123001
Zhou X, Garbinsky D, Ouyang J, Davenport E, Agarwal I, Oberdhan D. Longitudinal data on treatment duration and compliance from autosomal dominant polycystic kidney disease clinical trials with tolvaptan. Nephrol Dial Transplant. 2020 Jun;35(Supplement_3):gfaa139.S. doi: 10.1093/ndt/gfaa139.SO093
Zhou X, Davenport E, Ouyang J, Hoke M, Garbinsky D, Agarwal I, Oberdhan D. Population characteristics across an expanded pooled database of multiple autosomal dominant polycystic kidney disease clinical studies. Nephrol Dial Transplant. 2020 Jun;35(Supplement_3):gfaa142.P. doi: 10.1093/ndt/gfaa142.P0037
Beillat M, Brown TM, DiBenedetti DB, Naber D. Patient and caregiver perspectives on the Heinrichs-Carpenter Quality of Life Scale and the Subjective Well-being Under Neuroleptics-Short Form. J Psychiatry Psychiatric Disord. 2017 May;1(3):109-26.
Dickey H, Watson V, Zangelidis A. Is it all about money? An examination of the motives behind moonlighting. Appl Econ. 2010 Nov 3;43(26):3767-74. doi: 10.1080/00036841003724403